NYSE:ABBV - AbbVie News Headlines

$70.58
+0.07 (+0.10 %)
(As of 09/17/2019 02:50 AM ET)
Today's Range
$69.7229
Now: $70.58
$70.96
50-Day Range
$62.90
MA: $66.39
$70.9726
52-Week Range
$62.66
Now: $70.58
$96.60
Volume5.75 million shs
Average Volume8.00 million shs
Market Capitalization$104.35 billion
P/E Ratio8.92
Dividend Yield6.07%
Beta0.95

Headlines

AbbVie (NYSE ABBV) News Headlines

Source:
DateHeadline
AbbVie Inc (NYSE:ABBV) Sees Significant Growth in Short InterestAbbVie Inc (NYSE:ABBV) Sees Significant Growth in Short Interest
www.americanbankingnews.com - September 14 at 2:49 AM
AbbVie Stock Rises After UBS Upgrades To Buy - TheStreet.comAbbVie Stock Rises After UBS Upgrades To Buy - TheStreet.com
www.thestreet.com - September 13 at 1:15 PM
Consumer groups, unions urge caution on $63 billion AbbVie deal for Allergan - ReutersConsumer groups, unions urge caution on $63 billion AbbVie deal for Allergan - Reuters
www.reuters.com - September 13 at 1:15 PM
Buy AbbVie Stock, as Its Deal for Allergan Might Work, Analyst Says - BarronsBuy AbbVie Stock, as Its Deal for Allergan Might Work, Analyst Says - Barron's
www.barrons.com - September 13 at 1:15 PM
Anxious About AbbVie? Here Are 4 Things You Should Know - Motley FoolAnxious About AbbVie? Here Are 4 Things You Should Know - Motley Fool
www.fool.com - September 12 at 8:58 AM
Anxious About AbbVie? Here Are 4 Things You Should KnowAnxious About AbbVie? Here Are 4 Things You Should Know
www.fool.com - September 12 at 8:29 AM
AbbVie (NYSE:ABBV) Upgraded to "Buy" at UBS GroupAbbVie (NYSE:ABBV) Upgraded to "Buy" at UBS Group
www.americanbankingnews.com - September 12 at 7:33 AM
AbbVie Inc. (ABBV) CEO Rick Gonzalez Presents at Morgan Stanley Healthcare Conference (Transcript) - Seeking AlphaAbbVie Inc. (ABBV) CEO Rick Gonzalez Presents at Morgan Stanley Healthcare Conference (Transcript) - Seeking Alpha
seekingalpha.com - September 10 at 8:48 PM
AbbVie: The 6.5% Yield Window Wont Stay Open Much Longer - Seeking AlphaAbbVie: The 6.5% Yield Window Won't Stay Open Much Longer - Seeking Alpha
seekingalpha.com - September 10 at 3:48 PM
AbbVie Inc (NYSE:ABBV) Declares $1.07 -- DividendAbbVie Inc (NYSE:ABBV) Declares $1.07 -- Dividend
www.americanbankingnews.com - September 9 at 6:13 PM
3 Stocks to Buy With Dividends Yielding More Than 6%3 Stocks to Buy With Dividends Yielding More Than 6%
finance.yahoo.com - September 8 at 8:09 AM
Top Stock Reports for Microsoft, Home Depot & AbbVie - Yahoo FinanceTop Stock Reports for Microsoft, Home Depot & AbbVie - Yahoo Finance
finance.yahoo.com - September 7 at 10:22 AM
AbbVie Declares Quarterly Dividend - Yahoo FinanceAbbVie Declares Quarterly Dividend - Yahoo Finance
finance.yahoo.com - September 7 at 10:22 AM
AbbVie Inc Forecasted to Earn FY2019 Earnings of $9.04 Per Share (NYSE:ABBV)AbbVie Inc Forecasted to Earn FY2019 Earnings of $9.04 Per Share (NYSE:ABBV)
www.americanbankingnews.com - September 6 at 6:26 AM
Allergan: Why I Like This AbbVie Target - Seeking AlphaAllergan: Why I Like This AbbVie Target - Seeking Alpha
seekingalpha.com - September 6 at 5:37 AM
AbbVie Inc (NYSE:ABBV) SVP Nicholas Donoghoe Buys 7,525 SharesAbbVie Inc (NYSE:ABBV) SVP Nicholas Donoghoe Buys 7,525 Shares
www.americanbankingnews.com - September 4 at 5:59 PM
UPDATE: Abbvie (ABBV) Dermatologist Study Puts Skyrizi on Par With Enbrel, PT to $81 at Piper Jaffray - StreetInsider.comUPDATE: Abbvie (ABBV) Dermatologist Study Puts Skyrizi on Par With Enbrel, PT to $81 at Piper Jaffray - StreetInsider.com
www.streetinsider.com - September 4 at 3:12 PM
Idera teams up with AbbVie in cancer combo therapies - Seeking AlphaIdera teams up with AbbVie in cancer combo therapies - Seeking Alpha
seekingalpha.com - September 4 at 3:12 PM
3 Lessons From AbbVies $5.8 Billion Blunder With Cancer Drug Rova-T - Yahoo Finance3 Lessons From AbbVie's $5.8 Billion Blunder With Cancer Drug Rova-T - Yahoo Finance
finance.yahoo.com - September 4 at 3:12 PM
AbbVie Inc (NYSE:ABBV) Receives Average Recommendation of "Hold" from BrokeragesAbbVie Inc (NYSE:ABBV) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - September 4 at 2:47 PM
AbbVie (NYSE:ABBV) Price Target Increased to $81.00 by Analysts at Piper Jaffray CompaniesAbbVie (NYSE:ABBV) Price Target Increased to $81.00 by Analysts at Piper Jaffray Companies
www.americanbankingnews.com - September 4 at 11:31 AM
3 Lessons From AbbVies $5.8 Billion Blunder With Cancer Drug Rova-T - Motley Fool3 Lessons From AbbVie's $5.8 Billion Blunder With Cancer Drug Rova-T - Motley Fool
www.fool.com - September 4 at 9:49 AM
Idera Pharmaceuticals Announces Immuno-Oncology Clinical Research Collaboration with AbbVie - Yahoo FinanceIdera Pharmaceuticals Announces Immuno-Oncology Clinical Research Collaboration with AbbVie - Yahoo Finance
finance.yahoo.com - September 4 at 9:49 AM
3 Lessons From AbbVie's $5.8 Billion Blunder With Cancer Drug Rova-T3 Lessons From AbbVie's $5.8 Billion Blunder With Cancer Drug Rova-T
finance.yahoo.com - September 4 at 9:49 AM
Idera teams up with AbbVie in cancer combo therapiesIdera teams up with AbbVie in cancer combo therapies
seekingalpha.com - September 4 at 8:09 AM
AbbVie: Even Better Dividend Now - Seeking AlphaAbbVie: Even Better Dividend Now - Seeking Alpha
seekingalpha.com - September 3 at 8:03 PM
The Zacks Analyst Blog Highlights: J&J, Eli Lilly, Bristol-Myers, Roche and AbbVieThe Zacks Analyst Blog Highlights: J&J, Eli Lilly, Bristol-Myers, Roche and AbbVie
finance.yahoo.com - September 3 at 3:02 PM
Why Bank of America Says Dividend Stocks are the Only Play NowWhy Bank of America Says Dividend Stocks are the Only Play Now
finance.yahoo.com - September 3 at 3:02 PM
 Brokerages Expect AbbVie Inc (NYSE:ABBV) Will Announce Quarterly Sales of $8.38 Billion Brokerages Expect AbbVie Inc (NYSE:ABBV) Will Announce Quarterly Sales of $8.38 Billion
www.americanbankingnews.com - September 3 at 5:12 AM
3 High-Yield Dividend Stocks to Buy on Sale3 High-Yield Dividend Stocks to Buy on Sale
finance.yahoo.com - September 1 at 4:12 PM
 Analysts Anticipate AbbVie Inc (NYSE:ABBV) to Announce $2.28 EPS Analysts Anticipate AbbVie Inc (NYSE:ABBV) to Announce $2.28 EPS
www.americanbankingnews.com - September 1 at 2:20 AM
AbbVie Ends Rova-T Program as 3rd Lung Cancer Study Fails - Yahoo FinanceAbbVie Ends Rova-T Program as 3rd Lung Cancer Study Fails - Yahoo Finance
finance.yahoo.com - August 30 at 8:27 PM
Big Pharma kills signature drug at center of $5.8 billion South S.F. deal - San Francisco Business TimesBig Pharma kills signature drug at center of $5.8 billion South S.F. deal - San Francisco Business Times
www.bizjournals.com - August 30 at 8:27 PM
AbbVie is shutting down its troubled Rova-T R&D program - MarketWatchAbbVie is shutting down its troubled Rova-T R&D program - MarketWatch
www.marketwatch.com - August 30 at 8:27 PM
AbbVie Discontinues Phase III Trial of Drug to Treat Small-Cell Lung CancerAbbVie Discontinues Phase III Trial of Drug to Treat Small-Cell Lung Cancer
www.msn.com - August 30 at 3:20 PM
AbbVie Ends Work on Drug From $5.8 Billion Deal After FailuresAbbVie Ends Work on Drug From $5.8 Billion Deal After Failures
www.bloomberg.com - August 30 at 3:20 PM
Pharma Stock Roundup: JNJ's Opioid Lawsuit, Regulatory Nod for LLY, BMY, RHHBY DrugsPharma Stock Roundup: JNJ's Opioid Lawsuit, Regulatory Nod for LLY, BMY, RHHBY Drugs
finance.yahoo.com - August 30 at 11:39 AM
AbbVie Ends Rova-T Program as 3rd Lung Cancer Study FailsAbbVie Ends Rova-T Program as 3rd Lung Cancer Study Fails
finance.yahoo.com - August 30 at 11:39 AM
FDA flags risks from AbbVie, Gilead, Merck hepatitis C drugs to... - ReutersFDA flags risks from AbbVie, Gilead, Merck hepatitis C drugs to... - Reuters
www.reuters.com - August 29 at 8:08 PM
AbbVie Ends Work on Drug From $5.8 Billion Deal After Failures - BloombergAbbVie Ends Work on Drug From $5.8 Billion Deal After Failures - Bloomberg
www.bloomberg.com - August 29 at 8:08 PM
AbbVie Discontinues Phase III Trial of Drug to Treat Small-Cell Lung Cancer - TheStreet.comAbbVie Discontinues Phase III Trial of Drug to Treat Small-Cell Lung Cancer - TheStreet.com
www.thestreet.com - August 29 at 3:06 PM
Should You Buy AbbVie for the Dividend? - Yahoo FinanceShould You Buy AbbVie for the Dividend? - Yahoo Finance
finance.yahoo.com - August 29 at 3:06 PM
AbbVie bails on ADC Rova-T in lung cancer - Seeking AlphaAbbVie bails on ADC Rova-T in lung cancer - Seeking Alpha
seekingalpha.com - August 29 at 9:33 AM
UPDATE 1-FDA flags risks from AbbVie, Gilead, Merck hepatitis C drugs to certain patientsUPDATE 1-FDA flags risks from AbbVie, Gilead, Merck hepatitis C drugs to certain patients
finance.yahoo.com - August 29 at 9:33 AM
AbbVie Discontinues Rovalpituzumab Tesirine (Rova-T) Research and Development ProgramAbbVie Discontinues Rovalpituzumab Tesirine (Rova-T) Research and Development Program
finance.yahoo.com - August 29 at 9:33 AM
AbbVie terminates late-stage lung cancer trialAbbVie terminates late-stage lung cancer trial
finance.yahoo.com - August 29 at 9:33 AM
AbbVie is shutting down its troubled Rova-T R&D programAbbVie is shutting down its troubled Rova-T R&D program
finance.yahoo.com - August 29 at 9:33 AM
AbbVie Shareholders Can Earn 17% On Excess Cash Through Merger Arbitrage - Seeking AlphaAbbVie Shareholders Can Earn 17% On Excess Cash Through Merger Arbitrage - Seeking Alpha
seekingalpha.com - August 28 at 3:08 PM
BARCLAYS PLC UK Regulatory Announcement: Form 8.3 - ABBVIE INC - Business WireBARCLAYS PLC UK Regulatory Announcement: Form 8.3 - ABBVIE INC - Business Wire
www.businesswire.com - August 28 at 11:51 AM
Bristol-Myers' Empliciti Gets EMA Nod for Label ExpansionBristol-Myers' Empliciti Gets EMA Nod for Label Expansion
finance.yahoo.com - August 28 at 11:51 AM
This page was last updated on 9/17/2019 by MarketBeat.com Staff

Featured Article: What Are Cryptocurrencies?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel